Lindsay Young - Tempest Therapeutics Head Resources
| TPST Stock | USD 0.92 0.01 1.10% |
Executive
Lindsay Young is Head Resources of Tempest Therapeutics
| Address | 2000 Sierra Point Parkway, Brisbane, CA, United States, 94005 |
| Phone | 415 798 8589 |
| Web | https://www.tempesttx.com |
Tempest Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.5428) % which means that it has lost $0.5428 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.8926) %, meaning that it created substantial loss on money invested by shareholders. Tempest Therapeutics' management efficiency ratios could be used to measure how well Tempest Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.6 in 2024. Return On Capital Employed is likely to drop to -0.73 in 2024. At this time, Tempest Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 70.9 M in 2024, whereas Non Current Liabilities Total is likely to drop slightly above 13 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Michael Hassman | Scpharmaceuticals | N/A | |
| JD Esq | Seres Therapeutics | 69 | |
| MD FAAP | Lumos Pharma | N/A | |
| Eddie MBA | Lumos Pharma | N/A | |
| Steve Parsons | Scpharmaceuticals | N/A | |
| Lisa MD | Seres Therapeutics | 65 | |
| Caroline Holda | Seres Therapeutics | N/A | |
| John PharmD | Scpharmaceuticals | N/A | |
| MD MBA | Eliem Therapeutics | 50 | |
| David Ege | Seres Therapeutics | 49 | |
| Lee Flowers | HCW Biologics | 78 | |
| Jeffrey Nelson | Milestone Pharmaceuticals | 43 | |
| Nicole Esq | HCW Biologics | N/A | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
| Rachael Nokes | Scpharmaceuticals | 49 | |
| RPh Young | Seres Therapeutics | 57 | |
| Alpa Parikh | Lumos Pharma | N/A | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Carlo Tanzi | Seres Therapeutics | N/A | |
| Kim Fox | Milestone Pharmaceuticals | N/A | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
Management Performance
| Return On Equity | -2.89 | ||||
| Return On Asset | -0.54 |
Tempest Therapeutics Leadership Team
Elected by the shareholders, the Tempest Therapeutics' board of directors comprises two types of representatives: Tempest Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tempest. The board's role is to monitor Tempest Therapeutics' management team and ensure that shareholders' interests are well served. Tempest Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tempest Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dr Dubensky, Pres Director | ||
| Justin Trojanowski, Treasurer Controller | ||
| Nicholas Maestas, VP Secretary | ||
| RAC Sakai, Head Quality | ||
| Samuel MD, Executive Officer | ||
| Petpiboon Prasit, Acting Director | ||
| Anne Moon, Project Leadership | ||
| LLM JD, President CEO | ||
| Lindsay Young, Head Resources |
Tempest Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tempest Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.89 | ||||
| Return On Asset | -0.54 | ||||
| Current Valuation | 35.14 M | ||||
| Shares Outstanding | 43.64 M | ||||
| Shares Owned By Insiders | 0.24 % | ||||
| Shares Owned By Institutions | 23.02 % | ||||
| Number Of Shares Shorted | 2.64 M | ||||
| Price To Earning | 0.23 X | ||||
| Price To Book | 3.45 X | ||||
| EBITDA | (28.78 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Tempest Stock Analysis
When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.